News

Osteoarthritis Patients Are at Substantial Cardiovascular Risk


 

ROME — Cardiovascular risk profiles in osteoarthritis patients are, on average, comparable to those in patients with rheumatoid arthritis, according to a Dutch study.

In recent years, much attention has been focused on the elevated risk of cardiovascular events in patients with rheumatoid arthritis, as a consequence of their increased prevalence of the standard cardiovascular risk factors coupled with a further boost in risk resulting from the chronic systemic inflammatory disease process. The cardiovascular risk associated with osteoarthritis has received far less attention, Dr. Inger Meek said.

She determined the cardiovascular risk profiles of 285 consecutive rheumatoid arthritis patients and 112 consecutive osteoarthritis patients using the SCORE (Systematic Coronary Risk Evaluation) system, which is routinely employed in Europe in lieu of the Framingham risk score. The two groups were similar in terms of mean age and sex. The mean disease duration of the rheumatoid arthritis patients was 6.8 years.

In all, 18% of the osteoarthritis patients had a greater-than-10% estimated 10-year risk of a fatal cardiovascular event by SCORE, as did 15% of rheumatoid arthritis patients, according to Dr. Meek of the University of Twente in Enschede, the Netherlands.

Hypercholesterolemia was significantly more prevalent in the osteoarthritis patients (45%) than in the rheumatoid arthritis patients (29%).

The two groups did not differ significantly in terms of the other elements of SCORE (smoking status, systolic blood pressure, age, and sex).

The SCORE system, developed by the European Society of Cardiology, is based upon 3 million person-years of observation, and doesn't factor in body mass index, Dr. Meek noted. The prevalence of obesity is greatly increased in osteoarthritis patients. Thus, SCORE likely underestimates their cardiovascular mortality risk.

Recent evidence-based recommendations by the European League Against Rheumatism advise physicians to apply a 1.5 multiplication factor to the conventional cardiovascular mortality risk SCORE in rheumatoid arthritis patients who meet two of three criteria: disease duration greater than 10 years, rheumatoid factor or anti–cyclic citrullinated peptide positivity, or extra-articular disease manifestations (Ann. Rheum. Dis. 2010;69:325-31). This is designed to account for the heightened cardiovascular risk imposed by a high degree of systemic inflammation.

The high percentage of osteoarthritis patients in this study with a greater-than-10% estimated likelihood of cardiovascular death within 10 years is of concern, Dr. Meek stressed, because the prevalence of osteoarthritis is expected to mushroom as a result of the graying of the baby boom generation.

Dr. Johannes W.J. Bijlsma of the University Medical Center Utrecht (the Netherlands) commented that the take-home message of Dr. Meek's study is that physicians need to be aware that not only rheumatoid arthritis patients but also osteoarthritis patients are at increased cardiovascular risk.

Disclosures: Dr. Meek declared that she had no financial conflicts.

Recommended Reading

Tailored Tx Proves Successful for Fibromyalgia
MDedge Rheumatology
Osteoarthritis Patients Less Prone to Hip Fractures, Study Finds
MDedge Rheumatology
New RA Criteria Should Not Replace Judgment : RA classification is geared to studies with defined populations; diagnosis is for clinical management.
MDedge Rheumatology
Joint Erosions Persist Despite Response to Methotrexate
MDedge Rheumatology
Leflunomide-Rituximab Combo Effective in RA
MDedge Rheumatology
Coxibs Found to Trigger Fewer GI Events in RA
MDedge Rheumatology
Novel Topical Agent Eased Osteoarthritis Pain : Strontium chloride hexahydrate, also used in toothpaste for sensitive teeth, was well tolerated.
MDedge Rheumatology
Dietary Interventions Advised When Serum Urate Levels Reach 7 mg/dL
MDedge Rheumatology
Suicide Warning Added To Label of Tramadol
MDedge Rheumatology
Lack of Steroid Response Flags Biopsy Candidates in PMR
MDedge Rheumatology